| Name | Title | Contact Details |
|---|
CoreRx, Inc. is an industry leading Contract Development and Manufacturing Organization (CDMO), providing innovative drug formulation development, GMP manufacturing and packaging solutions to global pharmaceutical and bio-pharmaceutical partners. From its state-of-the-art, multi-site campus in Clearwater, Florida and its early product development center of excellence in San Rafael, California, CoreRx delivers value-added solutions to its partners, from clinic to commercial scale and across a range of dosage forms.
Chr. Hansen is a leading manufacturer of natural food color, with companies in over thirty countries, and color factories and application centers all over the world. Among the company's clients are some of the market leaders within the food and beverage
Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.
Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.